High intensity focused ultrasound for prostate cancer investigated at Indiana University School of Medicine

February 04, 2002

INDIANAPOLIS - Ultrasound technology, long known to expectant parents and used in the monitoring of fetal conditions, is making new waves at the Indiana University School of Medicine for its value in fighting prostate cancer.

A Phase I clinical trial at the IU School of Medicine investigates the efficiency and safety of using high intensity focused ultrasound (HIFU) for prostate cancer. The minimally invasive procedure combines the latest in 3-D technology to plot the location of cancerous cells and then fires ultra-focused sound waves to destroy them.

The IU School of Medicine one of two trial sites in the nation approved by the Food and Drug Administration late last year, the other being Case Western Reserve University in Cleveland, Ohio.

HIFU elevates tissue temperatures 70- to-90 degrees Centigrade (158-194 degrees Fahrenheit) in durations of up to four seconds, killing the cancer without damaging tissue surrounding the prostate, the small walnut-sized gland found at the base of the bladder.

"This minimally invasive surgical procedure is painless, bloodless and the energy from the ultrasound waves is non-ionizing and can be applied repeatedly," says Michael Koch, M.D., principal investigator of the trial and chairman of the school's Department of Urology. "We are enrolling 20 patients for this trial phase."

For more information about enrolling in HIFU trial, call 317-630-6044.

Among criteria for patients participating in the trial they must between 40 and 80 years old, have confined prostate cancer, no bleeding disorder and a prostate specific antigen level of 10 or less. PSA is a biological marker used in the early detection of prostate cancer. Patients who have failed previous external radiation for prostate cancer are also potential candidates.

The HIFU outpatient procedure can usually be completed within three hours, and the patient can go home after the anesthetic wears off. For cancer that is confined to the prostate, surgery and radiation are the common treatment options. Complete removal of the prostate can cause incontinence and impotence. Radiation therapy can cause rectal and bladder damage, impotence and difficult urination.

About 189,000 males in the United States are diagnosed annually with some form of prostate cancer, second only to lung cancer as deadly disease among men, reports the American Cancer Society. Although men can get the disease at any age, it's more common among those over 50 years old. Prostate cancer is twice as common in African Americans as it is in white American males.

The one-year clinical trial is based on initial HIFU research conducted at Kitasato University in Japan by urologist Toyoaki Uchida, M.D. The ultrasound device used is Sonablate ™.
-end-


Indiana University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.